Which treatment has recently been approved for neurogenic bladder management in spina bifida?

Which treatment has recently been approved for neurogenic bladder management in spina bifida?

• A. Botulinum Toxin (Botox)
• B. Anticholinergic Medication
• C. Intermittent Catheterization
• D. Surgical Intervention

Answer: (A)

Botulinum toxin A is used for neurogenic bladder management in spina bifida because it provides a targeted, reversible way to reduce detrusor overactivity. In many people with myelomeningocele, the bladder muscle squeezes involuntarily and with high pressure, which can lead to leakage and risk to kidney function. Injecting the toxin directly into the detrusor muscle relaxes those contractions by blocking acetylcholine release at the nerve terminals, increasing bladder capacity and improving storage. The effect is temporary, typically lasting several months, so treatments are repeated as needed. This approach offers a local, non-surgical option that can lessen or replace systemic anticholinergic meds and delay more invasive interventions. While other therapies like anticholinergic medications, intermittent catheterization, or surgical options remain important components of care, botulinum toxin injections provide a newer, bladder-targeted method with a favorable balance of efficacy and reversibility. Possible downsides include short-term urinary retention requiring catheterization, increased risk of urinary tract infections, and transient dysuria or hematuria, but many patients experience meaningful improvements in continence and quality of life.

Botulinum toxin A is used for neurogenic bladder management in spina bifida because it provides a targeted, reversible way to reduce detrusor overactivity. In many people with myelomeningocele, the bladder muscle squeezes involuntarily and with high pressure, which can lead to leakage and risk to kidney function. Injecting the toxin directly into the detrusor muscle relaxes those contractions by blocking acetylcholine release at the nerve terminals, increasing bladder capacity and improving storage. The effect is temporary, typically lasting several months, so treatments are repeated as needed. This approach offers a local, non-surgical option that can lessen or replace systemic anticholinergic meds and delay more invasive interventions.

While other therapies like anticholinergic medications, intermittent catheterization, or surgical options remain important components of care, botulinum toxin injections provide a newer, bladder-targeted method with a favorable balance of efficacy and reversibility. Possible downsides include short-term urinary retention requiring catheterization, increased risk of urinary tract infections, and transient dysuria or hematuria, but many patients experience meaningful improvements in continence and quality of life.